A Drug-Drug Interaction Study Between Sotagliflozin and Ramipril

ID: NCT03414723
Status: Recruiting
Phase: Phase 1
Start Date: January 15, 2018
First Submitted: January 18, 2018
Last Updated: February 22, 2018
Results: N/A
Organization: Sanofi
Sponsors & Collaborators: Sanofi
Location: Germany
Conditions: Diabetes Mellitus, Healthy Subjects
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

Study Description

Brief Summary

Primary Objective:

To evaluate the effects of multiple-dose ramipril on the steady state pharmacokinetic (PK) parameters of sotagliflozin and its main metabolite (sotagliflozin-3-O-glucuronide) in healthy male and female subjects.

Secondary Objectives:

- To assess the effects of multiple-dose sotagliflozin on the PK of ramipril and its active metabolite (ramiprilat).

- To assess the safety and tolerability of multiple-dose sotagliflozin with and without multiple-dose of ramipril.

Detailed Description

The expected duration of subject participation, including Screening of up to 29 days, Treatment Periods of 6 days and 11 days each with a Washout period of minimum of 7 days in between periods, Follow-up period of 6 days, and end-of-study-period of 10-14 days after last sotagliflozin dose, is approximately 66 days.
Condition or disease Intervention/treatment Phase

Diabetes Mellitus

Healthy Subjects

Drug: Sotagliflozin (SAR439954)
Other Names
Drug: Ramipril
Other Names
Phase 1

Tracking Information

First Submitted DateJanuary 18, 2018
Last Update Posted DateFebruary 22, 2018
Actual Start DateJanuary 15, 2018
Anticipated Completion DateMarch 01, 2018
Actual Primary Completion DateMarch 01, 2018
Results First Submitted DateN/A
Received Results Disposit DateN/A

Current Primary Outcome Measures

  • Assessment of PK parameter: AUCtau [Time Frame: On Day 10 (Period 2)]

    Sotagliflozin with ramipril: Area under the curve (AUC) to the end of the dosing period (AUCtau)

  • Assessment of PK parameter: AUCtau [Time Frame: On Day 5 (Period 1)]

    Sotagliflozin without ramipril: AUCtau

Original Primary Outcome Measures

Not Available

Current Secondary Outcome Measures

  • Assessment of PK parameter: Cmax [Time Frame: On Day 10 (Period 2)]

    Sotagliflozin with ramipril: Maximum plasma concentration (Cmax)

  • Assessment of PK parameter: Cmax [Time Frame: On Day 5 (Period 1)]

    Sotagliflozin without ramipril: Cmax

  • Assessment of PK parameter: tmax [Time Frame: On Day 10 (Period 2)]

    Sotagliflozin with ramipril: Time to reach Cmax (tmax)

  • Assessment of PK parameter: tmax [Time Frame: On Day 5 (Period 1)]

    Sotagliflozin without ramipril: tmax

  • Adverse events [Time Frame: Up to Day 37]

    Number of adverse events

Original Secondary Outcome Measures

Not Available

Study Design

Brief TitleA Drug-Drug Interaction Study Between Sotagliflozin and Ramipril
Official TitleAn Open Label, 2-treatment, 2-period, Single Sequence Study to Evaluate Pharmacokinetic Drug-drug Interaction Between Ramipril and Sotagliflozin at Steady State in Healthy Subjects
Brief Summary

Primary Objective:

To evaluate the effects of multiple-dose ramipril on the steady state pharmacokinetic (PK) parameters of sotagliflozin and its main metabolite (sotagliflozin-3-O-glucuronide) in healthy male and female subjects.

Secondary Objectives:

- To assess the effects of multiple-dose sotagliflozin on the PK of ramipril and its active metabolite (ramiprilat).

- To assess the safety and tolerability of multiple-dose sotagliflozin with and without multiple-dose of ramipril.

Detailed Description

The expected duration of subject participation, including Screening of up to 29 days, Treatment Periods of 6 days and 11 days each with a Washout period of minimum of 7 days in between periods, Follow-up period of 6 days, and end-of-study-period of 10-14 days after last sotagliflozin dose, is approximately 66 days.

Study TypeInterventional
Study PhasePhase 1
Estimated Enrollment
16
Allocation
Not Available
Interventional Model
Single Group Assignment
Masking
None (Open Label)
Primary Purpose
Basic Science
Conditions
Diabetes Mellitus
Healthy Subjects
Target Follow-Up Duration N/A
Biospecimen:
N/A
Sampling MethodN/A
Study PopulationN/A
Intervention
Drug: Sotagliflozin (SAR439954)

Pharmaceutical form: tablets Route of administration: oral

Other Names
Drug: Ramipril

Pharmaceutical form: tablets Route of administration: oral

Other Names
Study Groups/Cohorts
SAR439954 with or without ramipril
On Period 1, following an overnight fast, subjects will receive once daily single morning oral intake of sotagliflozin from Day 1 to Day 5 followed by the first meal that has to be started within 10 min after dosing. On Day 1 of the Period 2, study subjects will begin a 10-day ramipril regimen following an overnight fast. From Day 6 to Day 10, subjects will receive once daily single morning oral intake of ramipril concomitantly to the sotagliflozin dosing.

Study Arms
Experimental SAR439954 with or without ramipril
On Period 1, following an overnight fast, subjects will receive once daily single morning oral intake of sotagliflozin from Day 1 to Day 5 followed by the first meal that has to be started within 10 min after dosing. On Day 1 of the Period 2, study subjects will begin a 10-day ramipril regimen following an overnight fast. From Day 6 to Day 10, subjects will receive once daily single morning oral intake of ramipril concomitantly to the sotagliflozin dosing.
Drug : Sotagliflozin (SAR439954)
Pharmaceutical form: tablets Route of administration: oral

Experimental SAR439954 with or without ramipril
On Period 1, following an overnight fast, subjects will receive once daily single morning oral intake of sotagliflozin from Day 1 to Day 5 followed by the first meal that has to be started within 10 min after dosing. On Day 1 of the Period 2, study subjects will begin a 10-day ramipril regimen following an overnight fast. From Day 6 to Day 10, subjects will receive once daily single morning oral intake of ramipril concomitantly to the sotagliflozin dosing.
Drug : Ramipril
Pharmaceutical form: tablets Route of administration: oral

Arm Intervention/Treatment
Experimental SAR439954 with or without ramipril
On Period 1, following an overnight fast, subjects will receive once daily single morning oral intake of sotagliflozin from Day 1 to Day 5 followed by the first meal that has to be started within 10 min after dosing. On Day 1 of the Period 2, study subjects will begin a 10-day ramipril regimen following an overnight fast. From Day 6 to Day 10, subjects will receive once daily single morning oral intake of ramipril concomitantly to the sotagliflozin dosing.
Drug : Sotagliflozin (SAR439954)
Experimental SAR439954 with or without ramipril
On Period 1, following an overnight fast, subjects will receive once daily single morning oral intake of sotagliflozin from Day 1 to Day 5 followed by the first meal that has to be started within 10 min after dosing. On Day 1 of the Period 2, study subjects will begin a 10-day ramipril regimen following an overnight fast. From Day 6 to Day 10, subjects will receive once daily single morning oral intake of ramipril concomitantly to the sotagliflozin dosing.
Drug : Ramipril

Recruitment Information

Recruitment Status:Recruiting
Enrollment16
Completion DateMarch 01, 2018
Eligibility Criteria: Inclusion criteria :
- Healthy male or female subjects, between 18 and 55 years of age, inclusive.
- Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index between 18.0 and 32.0 kg/m², inclusive.
- Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).
- Normal vital signs after 10 minutes resting in supine position:
- 100 mmHg - 60 mmHg - 50 bpm - Standard 12-lead electrocardiogram (ECG) parameters after 10 minutes resting in supine position in the following ranges; 120 ms - Laboratory parameters within the normal range, unless the Investigator considers an abnormality to be clinically irrelevant for healthy subjects; however serum creatinine, alkaline phosphatase, hepatic enzymes (aspartate aminotransferase, alanine aminotransferase) should be strictly below the ULN. Total bilirubin out of normal range can be acceptable if total bilirubin should not exceed 1.5 the upper limit with normal conjugated bilirubin values (unless the subject has documented Gilbert syndrome).
- Female subject must use a double contraception method including a highly effective method of birth control except if she has undergone sterilization at least 3 months earlier or is postmenopausal. The accepted double contraception methods include the use of 1 of the following contraceptive options: (1) intrauterine device; (2) condom or diaphragm or cervical/vault cap, in addition to spermicide. Menopause is defined as being amenorrheic for at least 2 years with plasma follicle stimulating hormone (FSH) value being within the normal range for postmenopausal women according to the local laboratory. Hormonal contraception is NOT acceptable in this study due to drug interaction.
- Having given written informed consent prior to undertaking any study-related procedure.
Exclusion criteria:
- Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic, hematological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness.
- History of renal disease, or significant abnormal kidney function test with glomerular filtration rate (GFR) <90 mL/min as calculated using the Cockcroft-Gault equation.
- Frequent headaches and/or migraine, recurrent nausea and/or vomiting (more than twice a month).
- Blood donation, any volume, within 2 months before inclusion.
- Symptomatic postural hypotension, irrespective of the decrease in blood pressure, or asymptomatic postural hypotension defined as a decrease in systolic blood pressure ≥20 mmHg within 3 minutes when changing from supine to standing position.
- Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician.
- History or presence of drug or alcohol abuse (alcohol consumption more than 40 g per day on a regular basis).
- Smoking more than 5 cigarettes or equivalent per day, unable to stop smoking during the study.
- Excessive consumption of beverages containing xanthine bases (more than 4 cups or glasses per day)
- If female, pregnancy (defined as positive β-HCG blood test if applicable), breast-feeding.
- Any medication (including St John's Wort) within 14 days before inclusion or within 5 times the elimination half-life or pharmacodynamic half-life of the medication; any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion. Any oral contraceptives during the screening period or for at least 15 days prior to inclusion; any injectable contraceptives or hormonal intrauterine devices within 12 months prior to inclusion; or topical controlled delivery contraceptives (patch) for 3 months prior to inclusion.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
GenderAll
Age18 Years to 55 Years
Accepts Healthy VolunteersAccepts Healthy Volunteers
Contacts
Listed Location Countries
Germany

Administrative Information

NCT Number:NCT03414723
Other Study ID Numbers
INT14935
2017-002650-37
U1111-1196-5355
Has Data Monitoring CommitteeNo
U.S. FDA-regulated Product Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Device Product Not Approved or Cleared by U.S. FDA: No
IPD Sharing Statement
Not Available
Responsible Party,
Study Sponsor
Sanofi
Collaborators
Not Available
Investigators
Study Director
Clinical Sciences & Operations
Sanofi